New protein therapy hopes to repair brain damage in rare disease

NCT ID NCT06765733

Recruiting now Disease control Sponsor: Beijing Tiantan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tests a drug called Aleeto, a nerve repair protein made from stem cells, in 20 people with Multiple System Atrophy (MSA), a rare brain disease. The study checks if Aleeto is safe and might help with symptoms. Participants receive the drug via injection into the spine or vein.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Aleeto (a nerve repair protein derived from stem cells)
What this could lead to: If it works, this could point toward a treatment that repairs nerve damage and slows progression of Multiple System Atrophy.
What could go wrong: This is a very early, small trial (20 people) focused on safety, not proof of effectiveness. The treatment may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY (MSA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple system atrophy multiple system atrophy, parkinsonian type thyroid dyshormonogenesis 2A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SYSTEM ATROPHY (MSA) MULTIPLE SYSTEM ATROPHY - PARKINSONIAN SUBTYPE (MSA-P)

Contacts and locations

Locations

Beijing Tiantan Hospital, Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 100070, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.